Tolerability,Safety,Pharmacokinetic Profile and Immunogenicity of a Recombinant Humanized Anti-SARS-CoV-2 Monoclonal Antibody (JS016) for Injection in Chinese Health Subjects

COVID-19; and High Infection Risk of SARS-CoV-2 Clinical Trial

Official title: A Randomized, Double-blind, Placebo-controlled, Phase I Clinical Study to Evaluate the Tolerability, Safety, Pharmacokinetic Profile and Immunogenicity of JS016 (Anti-SARS-CoV-2 Monoclonal Antibody) Injection in Chinese Healthy Subjects After Intravenous Infusion of Single Dose

Status Recruiting

Clinical Trial Summary

This is a randomized, double-blind, placebo-controlled, phase I clinical study to evaluate the tolerability, safety, pharmacokinetic profile and immunogenicity of JS016 (anti-SARS-CoV-2 monoclonal antibody) injection in Chinese healthy subjects after intravenous infusion of single dose.Eligible patients will be injection JS016 (anti-SARS-CoV-2 monoclonal antibody)

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• COVID-19; and High Infection Risk of SARS-CoV-2

• NCT number: NCT04441918
• Study type: Interventional
• Source: Shanghai Junshi Bioscience Co., Ltd.
• Contact: Jing Zhang
• Phone: 021-52888189
• Email: 13816357098@163.com
• Status: Recruiting
• Phase: Phase 1
• Start date: June 5, 2020
• Completion date: December 11, 2020